





REFERENCES



R
E
F
E
R
E
N
C
E
S

REFERENCES

1. *Abbey DE, Burchette RJ, Knutsen SF, McDonell WF, Lebowitz MD, Enright PL, et al. (1998):* Long-term particulate and other air pollutants and lung function in non-smokers. *Am J Respir Crit Care Med*;158(1):289-98.
2. *Adams SG and Anzueto A, (2000):* Treatment of acute exacerbations of chronic bronchitis. In: *Antibiotics in Respiratory Infections*. A. Anzueto, ed. *Seminars Respir Infect*; 15: 234– 247.
3. *Agusti AG, Noguera A, Sauleda J, Sala E, Pons J and Busquets X, et al. (2003):* Systemic effects of chronic obstructive pulmonary disease. *Eur Respir J*;21(2):347-60.03;21(5):892-905.
4. *Agusti AG, (2005):* Systemic effects of chronic obstructive pulmonary disease. *Proc Am Thorac Soc*;2(4):367-70.
5. *AHIMA R.S and FLIER J.S,(2000):* Leptin. *Annu. Rev. Physiol*; 62:413–437.
6. *Alessi M.C., Bastelica D., Morange P, et al. (2000):* Plasminogen activator inhibitor 1, transforming growth factor-b1, and BMI are closely associated in human adipose tissue during morbid obesity. *Diabetes*; 49:1374–80.
7. *American Thoracic Society (ATS) (1995):* Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*;152:S77-121.
8. *American Thoracic Society(ATS) (2007):* Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease.*Amj Respir Crit Care Med* 2007;152:S77.
9. *Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK and Nelson NA, et al. (1987):* Antibiotic therapy in exacerbations of

- chronic obstructive pulmonary disease. *Ann Intern Med*; 106: 196-204.
10. *Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE and Connett JE, et al.(2005):* The effects of smoking cessation intervention on 14.5 year mortality: a randomized clinical trial. *Ann Intern Med*;142(4):233-9.
11. *Anzueto A., Fisher C.L. and Busman T, et al. (2001):* Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin/clavulanate tablets in the treatment of acute exacerbations of chronic bronchitis. *Clin Ther*; 23: 72–86.
12. *Arita, Y, Kihara, S, Ouchi, N, et al. (1999):* Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. *Biochem Biophys Res Commun*;257,79-83.
13. *ATS/ERS (2004):* Standards for the diagnosis and management of patients with COPD.
14. *ATS/ERS,(1999):*Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A statement of the American Thoracic Society and European Respiratory Society. *Am J Respir Crit Care Med*;159:S1–40
15. *Baarends E.M., Schols A.M., Mostert R, et al.(1997):* Peak exercise response in relation to tissue depletion in patients with chronic obstructive pulmonary disease. *Eur. Respir. J*; 10:2807–13.
16. *Badgett RG, Tanaka DJ, Hunt DK, Jelley MJ, Feinberg LE and Steiner JF, et al.(1993):* Can moderate chronic obstructive pulmonary disease be diagnosed by historical and physical findings alone? *Am J Med*; 94(2):188-96.
17. *Balmes J, Becklake M, Blanc P, Henneberger P, Kreiss K, Mopp C, Milton D, Schwartz D, Toren K, Viegi G, et al.(2003):* American

- Thoracic Society Statement: Occupational contribution to the burden of airway disease. *Am J Respir Crit Care Med*;167(5):787-97
18. *Barbera JA, Peinado VI and Santos S, et al. (2003):* Pulmonary hypertension in chronic obstructive pulmonary disease. *Eur Respir J*;21(5):892-905.
 19. *Barbera JA, Roca J, Ferrer A, et al. (1997):* Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. *Eur Respir J*, 10: 1285–1291.
 20. *Barnes PJ, Shapiro SD. and Pauwels RA. (2003):* Chronic obstructive pulmonary disease: molecular and cellular mechanisms. *Eur Respir J*;22:672-88
 21. *Barnes PJ, (2004A):* Macrophages as orchestrators of COPD. *J COPD*;1:59-70.
 22. *Barnes PJ, (2004B):* Mediators of chronic obstructive pulmonary disease. *Pharmacol Rev*;56(4):515-48.
 23. *Barnes PJ, (2010):* Chronic obstructive pulmonary disease: Effects beyond the lungs. National heart and Lung institute. *PloS Medicine/www.plosmedecine.org*.
 24. *Bastard J.P., Maachi M., Lagathu C, et al. (2006):* Recent advances in the relationship between obesity, inflammation, and insulin resistance. *Eur.Cytokine Netw*; 17:4–12.
 25. *Blanco I, Deserres FJ, Femandez-Bustillo E, Lara B, Miravettes M, et al. (2006):* Estimated numbers and prevalence PI*S and PI*Z alleles of alphas1-antitrypsin deficiency in european countries. *Eur Resp J*;27(1):77-84.
 26. *Bluher, M, Bullen, JW, Jr, Lee, JH, et al.(2006):* Circulating adiponectin and expression of adiponectin receptors in human skeletal muscle: associations with metabolic parameters and insulin resistance and

- regulation by physical training. *J Clin Endocrinol Metab*;91,2310-2316.
27. *Bolton CE., Ionescu AA., Shiels KM., Pettit RJ., Peter H., Edwards PH., Nixon LS., Evans WD. and Shale DJ. (2004):* Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary diseases. *American Journal of Respiratory and Critical Care Medicine* Vol. 170: 1286-1293.
28. *Bonnard C, Durand A, Vidal H, Rieusset J, et al.(2008):*"Changes in adiponectin, its receptors and AMPK activity in tissues of diet-induced diabetic mice". *Diabetes Metab*; 34 (1): 52-61.
29. *British Thoracic Society (BTS) (1997):* Guidelines for the management of chronic obstructive pulmonary disease. *Thorax*; 52 (Suppl 5): 51.
30. *Buist A.S., Mcburnie M.A., Vollmer W.M, et al. (2007):* International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. *Lancet*; 370:741-50.
31. *Burge s and wedzicha JA. (2003):* COPD exacerbations definitions and classifications. *Eur Respir J suppl* ;41:46s-53s.
32. *Burgel PR and Nadel JA. (2004):* Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production in airway epithelium. *Thorax*;59(11):992-6.
33. *Burrows B, Knudson RJ, Cline MG, Lebowitz MD, et al. (1977):* Quantitative relationships with chronic obstructive pulmonary disease. *Am Rev Respir Dis*;115(2):195-205
34. *Burrows B, Niden AH, Barclay WR and Kasik JE, et al. (1965):* Chronic obstructive lung disease II. Relationships of clinical and physiological findings to the severity of aiways obstruction. *Am Rev Respir Dis*;91:665-78.

35. *Cai D., Yuan M., Frantz D.F, et al. (2005):* Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. *Nat. Med*; 11:183-90.35.
36. *Calikoglu M., Sahin G., Unlu A., Ozturk C., Tamer L., Ercan B., Kanik A., Atik U, et al. (2004):* Leptin and TNF-alpha levels in patients with chronic obstructive pulmonary disease and their relationship to nutritional parameters. *Respiration* ;71:45-50.
37. *Calverley PMA, Leggett RJ, McElderry L and Flenley DC. (1982):* Cigarette smoking and secondary polycythemia in hypoxic cor pulmonale. *Am Rev Respir Dis*;125(5):507-10.
38. *Celli BR, Halbert RJ, Nordyke RJ, Schan B, et al. (2005):* Airway obstruction in never smokers: results from the Third National Health and Nutrition Examination Survey. *Am J Med*;118:1364-72
39. *Celli BR, MacNee W, ATS/ERS Task Force (2004):* Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *Eur Respir J*, 23: 932-946.
40. *Celli BR, Rassulo J and Make BJ, et al. (1986):* Dyssynchronous breathing during arm but not leg exercise in patients with chronic airflow obstruction. *N Engl J Med*;314(23):1485-90.
41. *Centers for Disease Control and Prevention,(2002):* Surveillance summaries. *MMWR*:51(NO.55-6).
42. *Cerveri I, Consico AG, Accordini S, Niniano R, Ansaldo E, Anto JM, et al.(2008):* Underestimation of airflow obstruction among young adults using FEV₁/FVC <70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes. *Thorax* Dec; 63(12):1040-5.
43. *Chambellan A, Chailleux E and Similowski T, et al.(2005):* Prognostic value of the hematocrit in patients with severe COPD receiving longterm oxygen therapy. *Chest*;128(3):1201-8.

44. *Chan-Yeung M, Ait-Khaled N, White N, Ip MS, Tan WC, et al. (2004):* The burden and impact of COPD in Asia and Africa. *Int J Tuberc Lung Dis*;8(1):2-14
45. *Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, et al. (2006):* Epidemiology and costs of chronic obstructive pulmonary disease. *Eur Respir J*;27(1):188-207
46. *Choi, BH; Kim, YH; Ahn, IS; Ha, JH; Byun, JM; Do, MS, et al. (2009):*"The inhibition of inflammatory molecule expression on 3T3-L1 adipocytes by berberine is not mediated by leptin signaling". *Nutr Res Pract* 3 (2): 84–88.
47. *Coates A. (1988):* Sources of error in flow-volume curves: Effect of expired volume measured at the mouth versus that measured in body plethysmography. *Chest*; 249:76-82.
48. *Combs TP, Berg AH, Rajala MW, et al.(2003):* Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. *Diabetes*; 52:268–76.
49. *Combs, T P, Berg AH, Obici S, Scherer PE, Rossetti L, et al.(2001):* Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. *J. Clin Invest*;108: 1875–81.
50. *Connors AF, Jr., Dawson NV, Thomas C, Harrell FE, Jr., Desbiens N and Fulkerson WJ, et al. (1996):* Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). *Am J Respir Crit Care Med*;154(4 Pt 1):959-67.
51. *Coppola A, Marfella R, Coppola L, Tagliamonte E, Fontana D, Liguori E, et al.(2008).* "Effect of weight loss on coronary circulation and adiponectin levels in obese women". *Int. J. Cardiol*;134 (3): 414–6.

52. *Cosio M , Sietta M , Agusti A, et al. (2009) : Immunologic aspects of chronic obstructive pulmonary disease. The new England Journal of Medicine ; 360:2445-2454.*
53. *Cosio M, Ghezzi H, and Hogg JC, (1978): The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med; 298:1277-1281.*
54. *Côté M, Mauriège P, Bergeron J, Alméras N, Tremblay A, Lemieux I, and Després J-P, (2005): Adiponectinemia in Visceral Obesity: Impact on Glucose Tolerance and Plasma Lipoprotein and Lipid Levels in Men. J Clin Endocrinol Metab;90: 1434-9.*
55. *Coxson HO, Chan IH, Mayo JR, Hlynsky J, Nakano Y, and Birmingham CL, (2004): Early emphysema In patients with anorexia nervosa. Am J Respir Crit Care Med;170(7):784-52.*
56. *Creutzberg EC. And Casaburi R, (2003): Endocrinological disturbances in COPD. Eur. Respir. J.,22 Suppl.46,76s-80s.*
57. *Criner G., Cordova FC., Leyenson V., Roy B., Travaline J. and Sudarshan S, et al.(1998): Effect of lung volume reduction surgery on diaphragm strength. Am J Respir Crit Care Med;157(5 Pt 1):1578-85.*
58. *Currie G.P. and Douglas J.G. (2007): Oxygen and inhalers. In ABC of chronic obstructive pulmonary disease. BMJ; 333:34-6.*
59. *Currie G.P. and Legge J.S. (2007): Diagnosis. In ABC of chronic obstructive pulmonary disease. BMJ; 332:1261-3.*
60. *Currie G.P. and Wedzicha J.A. (2007): Acute exacerbation. In ABC of chronic obstructive pulmonary disease. BMJ;333:87-9.*
61. *Dal Negro R. (2008): Optimizing economic outcomes in the management of COPD. International journal of chronic obstructive pulmonary disease ; 3(1):1-10*

62. *Dallman M.F., La Fleur S.E., Pecoraro N.C, et al. (2004):*Minireview: glucocorticoids – food intake, abdominal obesity, and wealthy nations in 2004. *Endocrinology*; **145**:2633–8.
63. *Danahay H and Jackson AD, (2005):* Epithelial mucus-hypersecretion and respiratory disease. *Curr Drug Targets Inflamm Allergy*;4:651-664.
64. *Dentener MA. Creutzberg EC, Schols AM, and Wouters EFM, (2001):* Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptorII during treatment of exacerbation. *Thorax*; 56:721-726.
65. *Diaz PT, King MA, Pacht ER, Wewers MD, Gadek JE, and Nagaraja HN, (2000):* Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. *Am Intern Med*;132(54):369-72.
66. *Díez JJ and Iglesias P, (2003):*"The role of the novel adipocyte-derived hormone adiponectin in human disease". *Eur. J. Endocrinol.* 148 (3): 293–300.
67. *Donahoe, M, Rogers, RM, and Wilson, DO, (1989):* Oxygen consumption of the respiratory muscles in normal and in malnourished patients with chronic obstructive pulmonary disease. *Am Rev Respir Dis*;140,385-391
68. *Edwards KM, Dupont WD, Westrich MK, Plummer WD, Jr., Palmer PS and Wright PF, (1994):* A randomized controlled trial of cold adapted and inactivated vaccines for the prevention of influenza A disease. *J Infect Dis*;169(1):68-76.
69. *Egyptian society of chest diseases and tuberculosis (ESCT) (2003):* The Egyptian guidelines for the management of chronic obstructive pulmonary disease. *Egypt J chest Dis andTub*;52(2):1-28

70. *Ehling A, Schäffler A, Herfarth H, Tarner IH, Anders S, Distler O, et al. (2006):*The potential of adiponectin in driving arthritis. *J Immunol*; 176: 4468-4478.
71. *Eid AA., Ionescu AA., Nixon LS. and Shale DJ, (2001):* Inflammatory response and body composition in chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.*, 164: 1414-1418.
72. *Eisner M.D., Blanc P.D., Sidney S, et al.(2007):* Body composition and functional limitation in COPD. *Respir. Res.*; 8:7.
73. *El-Khattib N., Sharaf El-Din M., Hamada GH, and Bakry N, (2006):* Study of osteoporosis and its possible pathophysiology in COPD. *Egyptian J Chest Dis and Tuberculosis*. July (in Press).
74. *Engelen M.P., Schols A.M., Does J.D, et al. (2000):* Skeletal muscle weakness is associated with wasting of extremity fat- free mass but not with airflow obstruction in patients with chronic obstructive pulmonary disease. *Am. J. Clin. Nutr*; 71:733-8.
75. *Fan VS, Ramsey SD, Giardino ND, Make BJ, Emery CF, Diaz PT, Benditt JO, Mosinefar Z, McKenna RJr, Curtis JL, Fishman AP, Martinez FJ, et al.(2007):* National emphysema treatment Trial (NETT) Research Group. Sex, depression and risk of hospitalization and mortality in chronic obstructive pulmonary disease. *Arch Intern Med*. 26;167(21):2345-53.
76. *Fessler HE. and Permutt S. (1998):* Lung volume reduction surgery and airflow limitation. *Am J Respir Crit Care Med*;157 (3 Pt 1):715-22.
77. *Finkelstein R, Fraser RS, Ghezzo H and Cosio MG, (1995):* Alveolar inflammation and its relation to emphysema in smokers. *Am J Respir Crit Care Med*; 152: 1666-1672.
78. *Fisher FF, Trujillo ME, HanifW, Barnett AH, McTernan PG, Scherer PE, et al. (2007):*Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. *Diabetologia*, 48: 1084-7.

79. *Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R and Ries A, (2008):* A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. *N Engl J Med* ;348:2059-73
80. *Fletcher C., Peto R., Tinker C, and Speiser FE, (1976):* The natural history of chronic bronchitis and emphysema. Oxford, University press.P:272
81. *Fruebis, J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, and Lodish HF, (2001):* Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. *Proc Natl Acad Sci USA*; 98: 2005–10.
82. *Funahashi T, Nakamura T, Shimomura I, Maeda K, Kuriyama H, Takahashi M, Arita Y, Kihara S, and Matsuzawa Y, (1999):* Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. *Intern Med*;38(2):202-6
83. *Fu Y, Luo N, Klein RL, Garvey WT, et al. (2005):* Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. *J Lipid Res*; 46: 1369-79.
84. *Gan WQ., Paul Man SF, and Sin DD, (2004):* The interactions between cigarette smoking and reduced lung function on systemic inflammation. *Chest*;127:558-564.
85. *Gartlehner G., Hansen RA., Carson SS. and Lohr KN, (2006):* "Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes". *Ann Fam Med* 4 (3):253-62.
86. *Georgopoulos D and Anthonisen NR, (1991):* Symptoms and signs of COPD. In: Cherniack NS, ed. *Chronic obstructive pulmonary disease*. Toronto: WB Saunders Co; 357-63.

87. *Global Initiative for Chronic Obstructive Lung Disease (2009)*: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD).
88. *GOLD (2010)*: global strategy for the diagnosis and prevention of chronic obstructive pulmonary disease. National Institutes of health, National Heart, Lung and Blood Institute and World Health Organization.
89. *Goldstein BJ and Scalia R. (2004)*: Adiponectin: A Novel Adipokine Linking Adipocytes and Vascular Function. *J Clin Endocrinol Metab*; 89: 2563-8.
90. *Goossens G.H. (2008)*: The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. *Physiol. Behav*; 94:206-18.
91. *Gotfried MH., De Abate A., Fogarty C. and Sokol WN. (2001)*: Comparison of 5-day, short course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis. *Clin Ther*; 23: 97-107.
92. *Gregg L. (1998)*: Manual of pulmonary function testing. 7th ed., chapter 2: 27; chapter 4: 69.
93. *Gross NJ. (2001)*: Extrapulmonary effects of chronic obstructive pulmonary disease. *Curr. Opin. Pulm.Med.*, 7:84-92.
94. *Grundey S.M., Brewer H.B. Jr, and Cleeman J.I, (2004)*: Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. *Circulation*; 109:433-8.
95. *Guerra, S, Sherrill, DL, and Bobadilla, A, (2002)*: The relation of body mass index to asthma, chronic bronchitis, and emphysema. *Chest*;122,1256-1263.

96. *Hak E, van Essen GA, Buskens E, Stalman W and de Melker RA, (1998):* Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht, The Netherlands. *J Epidemiol Community Health*;52(2):120-5.
97. *Halbert RJ, Isonaka S, George D, Iqbal A, et al. (2003):* Interpreting COPD prevalence estimates: what is the true burden of disease? *Chest*;123(5):1684-92
98. *Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM, et al. (2006):* Global burden of COPD: systemic review and meta-analysis. *Eur Resp J*.
99. *Haluzik M, Parizkova J, Haluzik MM, et al.(2004):* Adiponectin and its role in the obesity-related insulin resistance and related complications. *Physiol Res* ; 53: 123-9.
100. *Hanley AJG, Bowden D, Wagenknecht LE, Balasubramanyam A, Langfeld C, Saad Mf, et al. (2007):* Associations of Adiponectin with Body Fat Distribution and Insulin Sensitivity in Nondiabetic Hispanics and African-Americans. *J Clin Endocrinol Metab*; 92: 2665-71.
101. *Hansen NC., Skriver A., Brorsen-Riis L., Balslov S., Evald T., and Maltbaek N., (1994):* Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. *Respir Med*;88(7):531-5.
102. *Hara K, Yamauchi T, and Kadowaki T, (2005):* "Adiponectin: an adipokine linking adipocytes and type 2 diabetes in humans". *Curr. Diab. Rep.* 5 (2): 136-40.
103. *Hara, T, Fujiwara, H, and Nakao, H, (2005):*Body composition is related to increase in plasma adiponectin levels rather than training in young obese men. *Eur J Appl Physiol*;94,520-526

104. *Hill AT, Bayley D. and Stockley RA. (1999):* The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. *Am J Respir Crit Care Med*; 160:893-8.
105. *Hnizdo E, Sullivan PA, Bang KM, Wagner G, et al. (2002):* Association between chronic obstructive pulmonary disease and employment by industry and occupation in the US population: a study of data from the Third National Health and Nutrition Examination Survey. *Am J Epidemiol*;156(8):738-46
106. *Hogg J.C. and Timens W. (2009):* The pathology of chronic obstructive pulmonary disease. *Ann Rev Path Mech Dis* 4:455.
107. *Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM and Buzatu L (2004):* The nature of small-airway obstruction in chronic obstructive pulmonary disease. *N Engl J Med*;350(26):2645-53.
108. *Holleman DR. and Simel DL. (1995):* Does the clinical examination predict airflow limitation ?.*JAMA* 273(4):313-9.
109. *Hopkinson NS., Toma TP., Hansell DM. and Goldstraw P. (2005):* Effect of bronchoscopic lung volume reduction on dynamic hyperinflation and exercise in emphysema. *Am J Respir Crit Care Med* :171:453-60.
110. *Hosenpud JD, Bennett LE, Keck BM, Edwards EB and Novick RJ. (1998):* Effect of diagnosis on survival benefit of lung transplantation for end- stage lung disease. *Lancet*;351(9095):24-7.
111. *Hug C and Lodish HF, (2005):* "The role of the adipocyte hormone adiponectin in cardiovascular disease". *Curr Opin Pharmacol* 5 (2): 129-34.
112. *Hug C, Wang J, Ahmad NS, Bogan JS, TSao TS, Lodish HF, et al. (2004):* "T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin". *Proc Natl Acad Sci U S A* 101 (28): 10308-13.

113. *Hung WW., Wisnivesky JP., Siu AL. and Ross JS. (2009):* Cognitive decline among patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 180: 134–137.
114. *Ionescu AA. And Schoon E. (2003):* Osteoporosis in chronic obstructive pulmonary disease. *Eur. Respir. J.*, 22, Suppl. 46: 64s-75s.
115. *Irwin RS., Boulet LP., Cloutier MM., Fuller R., Gold PM. and Hoffstein V. (1998):* Managing cough as a defense mechanism and as a symptom. A consensus panel report of the American College of Chest Physicians. *Chest*;114(2 Suppl Managing):133S-81S
116. *Ito K, Ito M, Elliott WM, Cosio B, Caramori G and Kon OM (2005):* Decreased histone deacetylase activity in chronic obstructive pulmonary disease. *N Engl J Med*; 352(19):1967-76.
117. *Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE and Adams AL (2003):* Effectiveness of pneumococcal polysaccharide vaccine in older adults. *N Engl J Med*; 348(18):1747-55..
118. *Jindal SK., Aggarwal AN., Chaudhry K., Chhabra SK., D' Souza GA. and Gupta D. (2006):* A multicentric study on epidemiology of chronic obstructive pulmonary disease and its relationship with tobacco smoking and environmental tobacco smoking. *Indian J Chest Dis Allied Sci*; 48(1):23-9.
119. *Jones AT and Evans TW. (1997):* NO: COPD and beyond. *Thorax* 1997; 52 Suppl 3:S16-21.
120. *Jones RL and Nzekwu MMU, (2006):* The effects of body mass index on lung volumes. *Chest* 130: 827–833.
121. *Jubber A.S. (2004):* Respiratory complications of obesity. *Int. J. Clin. Pract*; 58:573–80.
122. *Kadowaki T, Yamauchi T, Kubota N, HaraK, Ueki K, Tobe K, et al.(2006):* Adiponectin and adiponectin receptors in insulin

- resistance, diabetes, and the metabolic syndrome. *J clin Invest*; 116: 1784-92.
123. *Kamischke A., Kemper DE., Castel MA, and Luthke M. (1998):* Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. *Eur. Respir. J.*, 11:41-45.
 124. *Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, et al. (2004):* Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. *Biochem Biophys Res Commun*; 314: 415-9.
 125. *Kern P.A., Ranganathan S., Li C, et al. (2001):* Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. *Am. J. Physiol. Endocrinol. Metab*; 280:E745-51.
 126. *Kershaw E.E and Flier J.S, (2004):* Adipose tissue as an endocrine organ. *J. Clin. Endocrinol. Metab*; 89:2548-56.
 127. *Kesten S. and Chapman KR (1993):* Physician perceptions and management of COPD. *Chest*; 104(1):254-8.
 128. *Kim KW, Shin YH, Lee KE, Kim ES, Sohn MH, Kim KE, et al. (2008):* Relationship between adipokines and manifestations of childhood asthma. *Pediatr Allergy Immunol* 19: 535-540.
 129. *Kirdar S, Serter M, Ceylan E, Sener AG, Kavak T, Karadag F, et al. (2009):* Adiponectin as a biomarker of systemic inflammatory response in smoker patients with stable and exacerbation phases of chronic obstructive pulmonary disease. *Scand J Clin Lab Invest* 69: 219-224.
 130. *Kishida K, Nagaretani H., Matsuda M., Komuro R., Ouchi N. et al(2001):* PPAR ligands increase expression and plasma

- concentration of adiponectin, an adipose derived protein Diabetes; 50:2094-2099.
131. Koz C, Uzun M, Yokusoglu M, Baysan O, Erinc K, Sag C, Hasimi A, Isik E, et al. (2007): Evaluation of plasma adiponectin levels in young men with coronary artery disease. *Acta Cardiol*; 62: 239-43.
 132. Kumada, M, Kihara, S, Sumitsuji, S, et al. (2003): Association of hypoadiponectinemia with coronary artery disease in men. *Arterioscler Thromb Vasc Biol*; 23, 85-89
 133. Lacasse Y., Brosseau L., Milne S. and Wong E. (2002): "Pulmonary rehabilitation for chronic obstructive pulmonary disease". Cochrane database of systematic reviews. Issue 4, Art No: CD003793. DOI: 10.1002/1465,858.CD003793.pub2.
 134. Lago F, dieguez C, Gomez-Reino j, Gualillo O, et al. (2007): Adipokines as emerging mediators of immune response and inflammation. *Nat Clin pract Rheumatol* 3:716-24.
 135. Lamb D, McLean A, Gillooly M, Warren PM, Gould GA and MacNee W. (1993): Relation between distal airspace size, bronchiolar attachments, and lung function. *Thorax*; 48: 1012-1017.
 136. Laperre TS, Sont JK, van Schadewijk A, et al. (2007): Smoking cessation and bronchial epithelial remodelling in COPD: a cross-sectional study. *Respir Res*; 8:85-93.
 137. Lara-Castro C, Fu Y, Chung BH, Garvey WT, et al. (2007): "Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease". *Curr. Opin. Lipidol.* 18 (3): 263-70.
 138. Laross CD, Gelissen HJ, Bergstein PG, Van den Bosch JM, Vanderschueren RG and Westermann CJ. (1986): Bullectomy for giant bullae in emphysema. *J Thorac Cardiovasc Surg*; 91(1):63-70.

139. *Lawlor D.A., Ebrahim S. and Davey S.G. (2005):* Association of birth weight with adult lung function: findings from the British Women's Heart and Health Study and a meta-analysis. *Thorax*;60(10):851-8.
140. *Li J., Zheng JP., Yuan JP., Zeng GQ., Zhong NS, and Lin CY. (2004):* Protective effect of a bacterial extract against acute exacerbation in patients with chronic bronchitis accompanied by chronic obstructive pulmonary disease. *Chin Med J (Engl)*;117(6):828-34.
141. *Liesker JJ., Wijkstra PJ., Ten Hacken NH., Postma DS, and Kerstjens HA. (2002):* A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD. *Chest* 121(2):597-608.
142. *Lightowler JV, Wedzicha JA, Elliott MW and Ram FS, (2003):* Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. *BMJ*;326:185
143. *Lior C, Molina J, Naberan K, Cots JM, Rose F and Miravittles M, (2005):* EVOCA study group. Exacerbations worsen the quality of life of chronic obstructive pulmonary disease patients in primary healthcare. *Int J Clin Pract* 62:585-592
144. *Liu H., Lazarus SC., Caughey GH, and Fahy JV, (1999):* Neutrophil elastase and elastase-rich cystic fibrosis sputum degranulate human eosinophils in vitro. *Am J Physiol*; 276:L 28-34.
145. *Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. (2006):* Chronic obstructive pulmonary disease: current burden and future projections. *Eur Respir J*;27(2):397-412.
146. *Maachi M., Pieroni L., Bruckert E, et al. (2004):* Systemic low-grade inflammation is related to both circulating and adipose tissue TNFa, leptin and IL6 levels in obese women. *Int. J. Obes. Relat. Metab. Disord*; 28:993-7.

147. *Maclay JD., McAllister DA., Mills NL., Paterson FP. and Ludlam CA. (2009):* Vascular dysfunction in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 180: 513–520.
148. *MacNee W. (2001):* Oxidative stress and lung inflammation in airways disease. *Eur J Pharmacol*;429(1-3):195-207.
149. *MacNee W. (2005):* Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. *Proc Am Thorac Soc*;2(1):50-60.
150. *MacNee W. (2007):* Pathology, pathogenesis and pathophysiology. In *ABC of chronic obstructive pulmonary disease. . BMJ*;332:1202–4 .
151. *Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K ,et al. (1996):* "cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1)". *Biochem. Biophys. Res. Commun*; 221 (2): 286–9.
152. *Maltais F, Ostinelli J, Bourbeau J, Tonnel A, Jacquemet N and Haddon J. (2004):* Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. *Am J Respir Crit Care Med*; 1654: 698–703.
153. *Mannino DM, (2005):* epidemiology and global impact of chronic obstructive pulmonary disease. *Semin Respir Crit. Care Med* 26:204-210.
154. *Mannino DM, Gagnon RC, Petty TL, Lydick E, et al. (2000):* Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey. *Arch Intern Med*;160(11):1683-9
155. *Mannino DM, Homa DM, Akinbami LJ, Ford ES, Red SC, et al.(2002):* Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. *MMWR Surveill Summ*;51(6):1-16

156. *Mannino DM, Thorn D, Swensen A, and Holguin F, (2008):* Prevalence and outcomes of diabetes, hypertension, and cardiovascular disease in chronic obstructive pulmonary disease. *Eur Respir J* 32: 962–969.
157. *Martinez FJ, Curtis JL, Sciurba F, Mimford J, Giardino ND, Weinmann G, Kazerooni E, Murray S, Criner GJ, Sin DD, Hogg J, Ries AL, Han M, Fishman AP, Make B, Hoffman EA, Mohsenifar Z, and Wise R, (2007):* National Emphysema Treatment Trial Research Group. Sex differences in severe pulmonary emphysema. *Am J Respir Crit Care Med* Aug 1;176(3):243-52.
158. *Masaki T, Chiba S, Yasuda T, Tsubone T, Kakuma T, Shimomura I, Funahashi T, Matsuzawa Y, Yoshimatsu H, et al. (2003):* Peripheral, But Not Central, Administration of Adiponectin Reduces Visceral Adiposity and Upregulates the Expression of Uncoupling Protein in Agouti Yellow (Ay/a) Obese Mice. *Diabetes*; 52: 2266-73.
159. *Matheson MC, Benke G, Raven J, Sim MR, Kromhout H, Vermeulen R, Johns DP, Walters EH, Abramson MJ, et al. (2005):* Biological dust exposure in the workplace is a risk factor for chronic obstructive pulmonary disease. *Thorax*;60(8):738-46
160. *Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI, et al. (1990):* Structure of a cannabinoid receptor and functional expression of the cloned CDNA. *Nature*; 346: 561–564.
161. *Matsuzawa, Y, Funahashi, T, Kihara, S, et al. (2004):* Adiponectin and metabolic syndrome. *Arterioscler Thromb Vasc Biol*; 24,29-33.
162. *McCloskey SC, Patel BD, Hinchliffe SJ, Reid ED, Wareham NJ, Lomas DA, et al. (2001):* Siblings of patients with severe chronic obstructive pulmonary disease have a significant risk of airflow obstruction. *Am J Resp Crit Care Med*;164(8 Pt 1):1419-24.
163. *Mehran RJ and Deslauriers J. (1995):* Indications for surgery and patient work-up for bullectomy. *Chest Surg Clin N Am* 1995;5(4):717-34.

164. *Menezes AM, Hallal PC, Perez-Padilla R, Jardim JR, Lopez MV, Valdivia G, Muino A, Montes de Oca M, Talamo C, Pertuze J, Victora CG, et al.(2007):* Laten American Project for the Investigation of Obstructive Lung Disease.(PLATINO) Team. Tuberculosis and airflow obstruction:evidence from the PLATINO study in Latina America. *Eur Respir J* Dec;30(6):1180-5. Epub 2007 Sep 5.
165. *Menezes AM, Perez-Padilla R, Jardim JR, Mueno A, Lopez MV, Valdivia G, et al. (2005):* chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. *Lancet*;366(9500):1875-81
166. *Miller MR., Hankinson J., Brusasco V., Burgos F., Casaburi R, and Coates A. (2005):* Standardisation of spirometry. *Eur Respir J.* ;26(2):319-38.
167. *Mills PR., Davies RJ, and Devalia JL. (1999):* Airway epithelial cells, cytokines and pollutants. *Am J Respir Crit Care Med*; 160: S38-43.
168. *Miravittles M., Murio C., Tirado-Conde G., Levy G., Muellerova H., Soriano JB, et al. (2008):* Geographic differences in clinical characteristics and management of COPD : the EPOCA study. *Int S Chron Obstruct Pulmon Dis*; 3:803-814.
169. *Mudler R., Chanez P., Campbell AM., Bousquet J., Heusser C, and Bullock GR, (1996):* Different cytokine patterns in bronchial biopsies in asthma and chronic bronchitis. *Respir Med*; 90:79-85.
170. *Murray CJL and Lopez AD, (1996):* editors .In: the global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard University press.
171. *Murray C.J and Lopez A.D, (2003):* Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. *Lancet*; 349:1498–504.

172. *Nakamura H, Yoshimarak, McELvaney NG, Crystal RG, et al. (1992):* Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. *J Clin Invest*; 89: 1478-1484.
173. *National Heart, Lung and Blood Institute, (1987):* Morbidity and mortality chartbook on cardiovascular, lung and blood diseases. Bethesda, Maryland:US Department of Health and Human Services, Public Health Service, National Institutes of Health
174. *National Heart, Lung and Blood Institute, (2004):* Morbidity and mortality chartbook on cardiovascular, lung and blood diseases. Bethesda, Maryland:US Department of Health and Human Services, Public Health Service, National Institutes of Health.
175. *Nathel L, Nathel M, Malmberg P, et al. (2007):* COPD diagnosis related to different guidelines and spirometry techniques. *Respir Res*; 4;8:89.
176. *Nedvídková J, Smitka K, Kopský V, Hainer V, et al. (2005):* "Adiponectin, an adipocyte-derived protein". *Physiol Res*; 54 (2): 133–40. PMID 15544426.
177. *Nici L, Donner C, Wouters E, ZuWallack R, Ambrosino N and Bourbeau J, (2006):* American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. *Am J Respir Crit Care Med*;173(12):1390-413.
178. *Nicolacakis K, Skowronski ME, Coreno AJ, West E, Nader NZ, Smith RL, McFadden ER Jr, et al. (2008):* Observations on the physiological interactions between obesity and asthma. *J Appl Physiol*; 105: 1533–1541.

179. *Niewoehner DE, Kleinerman J and Rice DB. (1974):* Pathologic changes in the peripheral airways of young cigarette smokers. *N Engl J Med*; 291: 755-758.
180. *Niewoehner DE., Collins D. and Erbland M. (2000):* Relation of FEV1 to clinical outcomes during exacerbations of chronic obstructive pulmonary disease *Am. J. Respir. Crit. Care Med.*, 1201-1205.
181. *O'Donnell DE., Aaron S., Bourbeau J. and Voduc N. (2007):* Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - update. *Can Respir J.*; 14 Suppl B:5B-32B.
182. *O'Donnell DE, Revill SM and Webb KA. (2001):* Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*;164(5):770-7.
183. *O'Shaughnessy TC., Ansari TW., Barnes NC, and Jeffery PK. (1997):* Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T-lymphocytes with FEV1. *Am J Respir Crit Care Med*; 155:882-7.
184. *Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P, et al. (2006):* Adiponectin: A key adipocytokine in metabolic syndrome. *Clin Sci (Lond)*;110(3):267-278.
185. *Oroczo-Levi M., Garcia -Aymerich J., Villar J., Ramirez-Sarmiento A., Anto JM, and Gea J. (2006):*Wood smoke exposure and risk of chronic obstructive pulmonary disease. *Eur Respir J*;27:542-6.
186. *Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gómez- Reino JJ, et al. (2006):* Changes in plasma levels of fat-derived hormones adiponectin ,leptin, resistin and visfatin in patients with rheumatoid arthritis. *Ann Rheum Dis*; 65: 1198-1201.
187. *Ouchi N., Kihara S., Funahashi T. et al.,(2003):* Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. *Circulation*; 107:671-4.

188. *Ouchi, N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, et al. (2000):* Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-KB signaling through a cAMPdependent pathway. *Circulation*, 102: 1296–301.
189. *Pannacciulli, N, Vettor, R, Milan, G, et al. (2003):* Anorexia nervosa is characterized by increased adiponectin plasma levels and reduced nonoxidative glucose metabolism. *J Clin Endocrinol Metab*;88,1748-1752.
190. *Pauwels RA, Buist AS, Calverley PM, Jenkins CR and Hurd SS. (2001):* Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. *Am J Respir Crit Care Med*;163:1256-76.
191. *Peinado VI, Barbera JA, Abate P and Rodriguez-Roisin R. (1999):* Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*; 159: 1605–1611.
192. *Pelosi P, Croci M, Ravagnan I, Tredici S, Pedoto A, Lissoni A, Gattinoni L, et al. (1998):* The effects of body mass on lung volumes, respiratory mechanics, and gas exchange during general anesthesia. *Anesth Analg* 87: 654–660.
193. *Permana P.A., Menge C., Reaven P.D, et al. (2006):* Macrophage-secreted factors induce adipocyte inflammation and insulin resistance. *Biochem. Biophys. Res. Commun*; 341:507–14.
194. *Pesci A, Majori M, Cuomo A and Gabrielli M. (1998):* Neutrophils infiltrating bronchial epithelium in chronic obstructive pulmonary disease. *Respir Med*; 92: 863–870

195. *Pinto-Plata VM., Mullerova H., Toso JF., Feudjo-Tepie M., Soriano JB, and Vessey RS. (2006):* C-reactive protein in patients with COPD, control smokers and non-smokers. *Thorax*, 61:23-28
196. *Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB, et al. (2004):* Plasma adiponectin levels and risk of myocardial infarction in men. *JAMA*, 291:1730-7.
197. *Pitcher, WD and Cunningham, HS, (1993):* Oxygen cost of increasing tidal volume and diaphragm flattening in obstructive pulmonary disease. *J Appl Physiol*;74,2750-2756.
198. *Polkey, MI, Kyroussis, D, Hamnegard, CH, et al. (1996):* Diaphragm strength in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*;154,1310-1317.
199. *Poole PJ and Black PN (2001):* Mucolytic agents for chronic bronchitis and chronic obstructive pulmonary disease: systematic review. *BMJ*; 322: 1271.
200. *Poole PJ, Veale AG, and Black PN, (1997):* The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*;157(6 Pt 1):1877-80
201. *Postma DS., Ten Hanchen NHT., Kerstjens HAM. and Koeter GH, (1999):* Home treatment of COPD exacerbation. *Thorax*, 54(suppl 2):58-513.
202. *Poulain M., Doucet M., Major G.C. et al. (2006):* The effect of obesity on chronic respiratory diseases: pathophysiology and therapeutic strategies. *CMAJ*; 174:1293-9.
203. *Prescott E., Lange P., and Vestbo J. (1998):* Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. *Eur Respir J*; 13(5):1109-14.

204. *Rabe KF, Hurd S, Anzueto A and Zielinski J (2007):* "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary". *Am. J. Respir. Crit. Care Med.* 176 (6): 532–55.
205. *Rahman I. (2005):* Oxidative stress in pathogenesis of chronic obstructive pulmonary disease: cellular and molecular mechanisms. *Cell Biochem Biophys*;43(1):167-88.
206. *Rajala RW and Scherer PE, (2003): Minireview.,* The Adipocyte At the Crossroads of Energy Homeostasis, Inflammation, and Atherosclerosis. *Endocrinology*; 144: 3765-73.
207. *Reid L. (1960):* Measurement of the bronchial mucous gland layer: a diagnostic yardstick in chronic bronchitis. *Thorax*; 15:132-41.
208. *Renaldi O, Pramono B, Sinorita H, Purnomo LB, Asdie RH, Asdie AH, et al. (2009):* "Hypoadiponectinemia: a risk factor for metabolic syndrome". *Acta Med Indones* 41 (1): 20–4. PMID 19258676.
209. *Rennard SI. (1990):* Inflammation and repair processes in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*; 160: S12–S16.
210. *Report of the Medical Research Council Working Party. (1981):* Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. *Lancet*;1(8222):681-6.
211. *Roberts CM, Bugler JR, Melchor R, Hetzel MR and Spiro SG. (1993):* Value of pulse oximetry in screening for long-term oxygen therapy requirement. *Eur Respir J*;6(4):559-62.
212. *Rodriguez-Roisin R. (2000):* Towards a consensus definition for COPD exacerbations. *Chest* 117: 3958-4015.
213. *Rodriguez-Roisin R. (2006):* COPD exacerbations.5: management. *Thorax*;61(6):535-44.

214. *Rodriguez-Roisin R. and MacNee W. (1998):* Pathophysiology of chronic obstructive pulmonary disease. In: Postma DS, Siafakas NM, eds. Management of chronic obstructive pulmonary disease. European Respiratory Monograph;3:107-26.
215. *S.Stanciu, Mihaela Iordache, Andreia Busuioceanu, G. Tanaseanu, M.Muresan and M.A Bogdan. (2009):* The Metabolic and Inflammatory Profile in Obese Patients with Chronic Obstructive Pulmonary Disease. Rom.J. Intern. Med;47,2,123-132
216. *Sabit R, Bolton CE, Edwards PH, Pettit RJ and Evans WD (2007):* Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175: 1259–1265.
217. *Saetta M, Di Stefano A, Turato G and Fabbri LM (1998):* CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med; 157: 822–826.
218. *Saetta M, Turato G, Maestrelli P, Mapp CE and Fabbri LM (2001):* Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med;163(6):1304-9.
219. *Sahebji H. (1998):* Dyspnea in obese healthy men. Chest; 114: 1373–1377.
220. *Salome CM, Munoz PA, Berend N, Thorpe CW, Schachter LM, and King GG, (2008):* Effect of obesity on breathlessness and airway responsiveness to methacholine in non-asthmatic subjects. Int J Obes 32: 502–509.
221. *Salpeter SR., Buckley NS, and Salpeter EE. (2006):* Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med 21(10):1011-9.
222. *Schachter LM, Salome CM, Peat JK, Woolcock AJ, et al. (2001):* Obesity is a risk for asthma and wheeze but not airway hyperresponsiveness. Thorax; 56: 4–8.

223. *Schellevis SH, van de Lisdonk EH, van deR Velden J, Hoogbergen SH, van Eijk JT and Van Well C, (1994):* Consultation rates and incidence of intercurrent morbidity among patients with chronic disease in general practice. *Br J gen Pract*;44(383):259-62

224. *Schols A.M., Broekhuizen R., Weling-Scheepers C.A, et al. (2005):* Body composition and mortality in chronic obstructive pulmonary disease. *Am. J. Clin. Nutr*; **82**:53–9.

225. *Schols A.M., Soeters P.B., Dingemans A.M, et al. (1993):* Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. *Am. Rev. Respir. Dis*; **147**:1151–6.

226. *Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB, et al. (2005):* Adiponectin and future coronary heart disease events among men with type 2 diabetes. *Diabetes*; **54**: 534–9.

227. *Schuurmans MM., Diacon AH, and Bolliger CT, (2002):* Functional evaluation before lung resection. *Clin Chest Med*;23(1):159-72.

228. *Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, and Wedzicha JA (2000):* Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, **161**: 1608–1613.

229. *Sethi S, Maloney J, Grove L, Wrona C, Berenson CS, et al. (2006):* Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*;173: 991-8.

230. *Sevenoaks MJ and Stockley RA, (2006):* Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity-a common inflammatory phenotype? *Respir Res*; **7**: 70.

231. *Sezer H, Akkurt I, Guler N, Marakoglu K, Berk S, et al. (2006):* A case-control study on the effect of exposure to different substances on the development of COPD. *Ann Epidemiol*;16(1):59-62
232. *Shaheen SO, Barker DJ, Shiell AW, Crocker FJ, Wield GA, Holgate ST, et al. (1994):* The relationship between pneumonia in early childhood and impaired lung function in late adult life. *Am J Respir Crit Care Med*;149(3 pt 1):616-9.
233. *Shapiro L and Scherer PE. (1998):* "The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor". *Curr. Biol.* 8 (6): 335-8. doi:10.1016/S0960-9822(98)70133-2. PMID 9512423
234. *Sharp JT, Henry JP, Swaeny SK, Meadows WR, Pietras RJ, et al. (1964):* The total work of breathing in normal and obese men. *J Clin Invest* 43: 728-739
235. *Shore S.A and Fredberg J.J. (2005):* Obesity, smooth muscle, and airway hyperresponsiveness. *J. Allergy Clin. Immunol*; 115:925-7.
236. *Siafakas N.M. and Bouros D. (1998):* Management of acute exacerbation of chronic obstructive pulmonary disease. In: Postma DS, Siafakas NM, eds. *Management of chronic obstructive pulmonary disease*. Sheffield: ERS Monograph;:264-77.
237. *Siafakas NM., Vemeire P., Pride NB, and Postma DS. (1995):* Optimal assessment and management of chronic obstructive pulmonary disease. *Eur Resp J.* 8: 1398.
238. *Silva GE, Sherill DL, Guerra S, Barbee RA, et al. (2004):* Asthma as a risk factor for COPD in a longitudinal study. *Chest*;126(1):59-65.
239. *Silverman EK, Palmer LJ, Mosley JD, Barth M, Senter JM and Brown A, (2002):* Genome wide linkage analysis of quantitative spirometric phenotypes in severe early-onset chronic obstructive pulmonary disease. *Am J Hum Genet*;70(5):1229-39.

240. *Silverman EK, Wiess ST, Drazen JM, Chapman HA, Carvey V, Campbell EJ, et al (2000):* Gender-related differences in severe, early-onset chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*;162(6):2152-8.
241. *Similowski T., Agusti A.G., MacNee W. and Schonhofer B. (2006):* The potential impact of anaemia of chronic disease in COPD. *Eur Respir J*;27(2):390-6.
242. *Simon P.M., Schwartzstein R.M., Weiss J.W., Fencel V., Teghtsoonian M. and Weinberger S.E, (1990):* Distinguishable types of dyspnea in patients with shortness of breath. *Am Rev Respir Dis*;142(5):1009-14.
243. *Sin D.D. and Man S.F.P. (2006):* Skeletal muscle weakness, reduced exercise tolerance, and COPD: is systemic inflammation the missing link? *Thorax*; 61:1-3 doi:10.1136/thx.2005.044941
244. *Sin DD, Jones RL, Man SF, et al. (2002):* Obesity is a risk factor for dyspnea but not for airflow obstruction. *Arch Intern Med*; 162: 1477-1481.
245. *Skurk T., Alberti-Huber C., Herder C. et al., (2007):* Relationship between adipocyte size and adipokine expression and secretion. *J. Clin. Endocrinol. Metab*; 92:1023-33.
246. *Slemenda CW., Christian JC., Reed T, and Johnston CC, (1992):* Long term bone loss in men: effects of genetic and environmental factors. *Ann Intern med.*, 117, 286-291.
247. *Smith C.A. and Harrison D.J, (1997):* Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. *Lancet*;350(9078):630-3.
248. *Snider GL., Kleinerman J., Thurlbeck WM, and Bengali ZK, (1985):* The definition of emphysema: report of a National Heart, Lung and

- Blood Institute, Division of Lung Diseases, Workshop. Am Rev Respir Dis, 132: 182–185.
249. *Soriano JB, visick GT, Muellerova H, Payvandi N, Hansell AL, et al.(2005):*Pattern of comorbidities in newly diagnosed COPD and asthma in primary care. Chest;128(4):2099-107
250. *Spanagel R and Weiss F,(1999):* The dopamine hypothesis of reward: past and current status. Trends Neurosci; 22: 512–527.
251. *Stanciu S and Bogdan M.A. (2008):* Bronhopneumopatia obstructivă cronică – boală sistemică inflamatorie cu risc cardiometabolic crescut. Stetoscop; 71: 15–17.
252. *Stavem K, Aaser E, Sandvik L, Bjornholt JV, Erikssen J, Thaulow E, et al.(2005):* Lung function, smoking and mortality in a 26-year follow-up of healthy middle-aged males. Eur Respir J;25(4):618-25
253. *Stefan, N, Vozarova, B, Funahashi, T, et al. (2002):*Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes;51,1884-1888.
254. *Stein CE, Kumaran K, Fall CH, Shaheen SO, Osmond C, Barker DJ, et al. (1997):* Relation of fetal growth to adult lung function in south India. Thorax;52(10):895-9.
255. *Sternfeld B., Ngo L., Satariano W.A,et al. (2002):* Associations of body composition with physical performance and selfreported functional limitation in elderly men and women. Am. J. Epidemiol.; 156:110–21.
256. *Stewart L. and Voekel N.F.(2008):* Molecular pathogenesis of emphysema. J Clin Invest. 118:394.

257. *Stockley R.A., O'Brien C., Pye A. and Hill S.L. (2000):* Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. *Chest*;117(6):1638-45.
258. *Stockley R.A. (2002):* Neutrophils and the pathogenesis of COPD chest ;121:151S-155S.
259. *Stoller JK, and Aboussouan LS. (2005):* Alpha-1 antitrypsin deficiency. *Lancet*; 365(9478):2225-36.
260. *Summer R, Little FF, Ouchi N, Takemura Y, Aprahamian T, Dwyer D, Fitzsimmons K, Suki B, Parameswaran H, Fine A, Walsh K, et al. (2008):* Alveolar macrophage activation and an emphysema-like phenotype in adiponectin-deficient mice. *Am J Physiol Lung Cell Mol Physiol* 294, L1035–L1042.
261. *Sutton BS, Weinert S, Langefeld CD, Williams AH, Campbell JK, Saad MF, Haffner SM, Norris JM, Bowden DW, et al. (2005):* Genetic analysis of adiponectin and obesity in Hispanic families: the IRAS Family Study. *Hum Genet*, 117: 107–18.
262. *Swanson R.N., Lainez-Ventosilla A., De Salvo M.C, and Amsden G.W, (2002):* Three-day azithromycin 500 mg q.i.d. vs 10-day clarithromycin 500 mg b.i.d. for acute exacerbation of chronic bronchitis in adults. *Am J Respir Crit Care Med*; I65: A269.
263. *Tager I.B., Segal M.R., Speizer F.E, and Weiss S.T, (1988):* The natural history of forced expiratory volumes. Effect of cigarette smoking and respiratory symptoms. *Am Rev Respir Dis*;138(4):837-49.
264. *Tager IB, Ngo L, Hanrahan JP, et al. (1995):* Maternal smoking during pregnancy. Effects on lung function during the first 18 months of life. *Am J Respir Crit Care Med*;152:977-83
265. *Takahashi M., Funahashi T., Shimomura I., Miyaoka Y., Matsuzawa Y, et al. (1996):* Plasma leptin levels and body fat distribution. *Horm. Metab. Res*; **28**: 751–752

266. *Talat AM (2002):* British Thoracic Society (BTS) (1997): Guidelines for the management of chronic obstructive pulmonary disease. *Thorax*; 52 (Suppl 5): 51.
267. *The Health Consequences of Involuntary Exposure to Tobacco Smoke (2006):* A Report of the Surgeon General, Department of Health and Human Services. Washington, DC, US.
268. *Thomas PS and Milledge JS, (1989):* Respiratory function in the morbidly obese before and after weight loss. *Thorax*; 44: 382–386.
269. *Tirimanna PR, vanSchayck CP, den Otter JJ, van Weel C, van Herwaarden CL, van den Boom G, et al. (1996):* Prevalence of asthma and COPD in general practice in 1992: has it changed since 1977? *Br J Gen Pract*;46(406):277-81
270. *Tomoda K, Yoshikawa M, Itoh T, Tamaki S, Fukuoka A, Komeda K, Kimura H, et al. (2007):* Elevated circulating plasma adiponectin in underweight patients with COPD. *Chest*; 132: 135–140.
271. *Trulock EP. (1997):* Lung transplantation. *Am J Respir Crit Care Med*;155(3):789-818.
272. *Turner MO., Patel A., Ginsburg S., et al. (1997):* Bronchodilator delivery in acute airflow obstruction. A meta-analysis. *Arch Intern Med*; 157: 1736–1744.
273. *Ukkola O and Santaniemi M (2002):*"Adiponectin: a link between excess adiposity and associated comorbidities?". *J. Mol. Med.* 80 (11): 696–702. doi:10.1007/s00109-002-0378-7. PMID 12436346.
274. *US Centers for Disease Control and Prevention (1995):* Criteria for a recommended standard:occupational exposure to respirable coal mine dust. Morgantown, WV:National Institute of Occupational Safety and Health. Publication NO.95-1036.

275. *US Surgeon General. (1984):* The health consequences of smoking: chronic obstructive pulmonary disease. Washington, D.C: US Department of Health and Human Services.
276. *Uzun K., Atalay H, and Inal A, (2007):* Thyroid hormone levels in patients with acute exacerbation of chronic obstructive pulmonary disease. *European Journal of General Medicine*, Vol. 4 No. 2: 80-82.
277. *Van Weel C. and Schellevis FG, (2006):* Comorbidity and guidelines: conflicting interests. *Lancet*; 367(9510):550-1.
278. *Verty ANA, McFarlane JR, McGregor IS, Mallet PE, et al.(2004):* Evidence for an interaction between CB₁ cannabinoid and melanocortin MCR-4 receptors in regulating food intake. *Endocrinology*; 145: 3224–3231.
279. *Visser M., Langlois J., Guralnik J.M, et al. (1998):* High body fatness, but not low fat-free mass, predicts disability in older men and women: the Cardiovascular Health Study. *Am. J. Clin. Nutr*; 68:584–90.
280. *Vonk JM, Jongepier H, Panhuysen CI, Schouten JP, Bleecker ER, Postma DS, et al. (2003):* Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 62 years of follow up. *Thorax*;58(4):322-7.
281. *Waki H, Yamauchi T, Kadowaki T, et al. (2010):* "[Regulation of differentiation and hypertrophy of adipocytes and adipokine network by PPAR gamma]" (in Japanese). *Nippon Rinsho* 68 (2): 210–6.
282. *Watson RA and Pride NB, (2005):* Postural changes in lung volumes and respiratory resistance in subjects with obesity. *J Appl Physiol* 98: 512–517.
283. *Watz H, Waschki B, Kirsten A, Muller KC, and Kretschmar G, (2009):* The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. *Chest* 136: 1039–1046.

284. *Wedzicha J.A. (2001):* Mechanisms of exacerbations. Novartis Found Symp, 234: 84–93.
285. *Wedzicha J.A. (2002):* Exacerbations: etiology and pathophysiologic mechanisms. Chest, 121(5):136S-141S. Ref ID: 19254.
286. *Weisberg S.P., Mccann D., Desai M, et al. (2003):* Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest; 112:1796–808.
287. *Wert SE,(2008):* Does adiponction play a role in pulmonary emphyse?
288. *Weyer C., Funahashi T., Tanaka S, et al. (2001):* Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab; 86:1930–5.
289. *White AJ., Gompertz S. and Stockley RA. (2003):* Chronic obstructive pulmonary disease . 6: The aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax;58(1):73-80.
290. *Wilson DO, Rogers RM, Wright EC, Anthonisen NR, et al. (1989):* Body weight in chronic obstructive pulmonary disease. The National Institutes' of Health Intermittent Positive-Pressure Breathing Trial. Am Rev Respir Dis;139(6):1435-8.
291. *Wilson R., Schentag J.J. and Ball P. (2002):* A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther; 24: 639–652.
292. *Wolf I, Sadetzki S, Kanety H, et al. (2006):* Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer; 106:966–973
293. *Womack CJ, Harris DL, Katzel LI, Hagberg JM, Bleecker ER, Goldberg AP,et al. (2000):* Weight loss, not aerobic exercise,

improves pulmonary function in older obese men. *Journal of Gerontology: Medical Sciences* 55A: M453–M457.

294. *Wongsurakiat P., Lertakyamanee J., Maranetra KN., Jongriratanakul S. and Sangkaew S. (2003):* Economic evaluation of influenza vaccination in Thai chronic obstructive pulmonary disease patients. *J Med Assoc Thai*;86(6):497-508.
295. *Wongsurakiat P., Maranetra KN., Wasi C., Kositanont U., Dejsomritrutai W. and Charoenratanakul S. (2004):* Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. *Chest*; 125 (6): 2011-20.
296. *World Health Organization. (2004):* Overweight and obesity: a new nutrition emergency? Monitoring the rapidly emerging public health problem of overweight and obesity: the WHO global database on body mass index. *SCN News*:5–12.
297. *World Health Organization. (2007):* Obesity: preventing and managing the global epidemic. Report of a WHO Consultation.
298. *World Health Organization (2008):* Tobacco Free Initiative- Policy recommendations for smoking cessation and treatment of tobacco dependence.
299. *Wouters EF, Groenewegen KH, Denterner MA, Vernooij JH, et al. (2007):* Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations. *Proc Am Thorac Soc*; 4: 626-634.
300. *Wouters EF. (2002):* Chronic obstructive pulmonary disease: 5: systemic effects of COPD. *Thorax*;57:1067–1070.
301. *Wright JL, Lawson L, Pare PD and Hogg JC (1983):* The structure and function of the pulmonary vasculature in mild chronic obstructive pulmonary disease. The effect of oxygen and exercise. *Am Rev Respir Dis*; 128: 702–707.

302. *Wright JL, Levy RD and Churg A. (2005):* Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. *Thorax*;60(7):605-9.
303. *Wu L, Chau J, Young RP, Pokomy V, Mills GD, Hopkins R, et al. (2004):* Transforming growth factor-Beta 1 genotype and susceptibility to chronic obstructive pulmonary disease. *Thorax*;59(2):126-9.
304. *Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME, et al. (2004):* Adiponectin differentially regulate cytokines in porcine macrophages. *Biochem Biophys Res Commun*; 316:924-9.
305. *Xu X, Weiss ST, Rijcken B, Schouten JP, et al. (1994):* Smoking, changes in smoking habits and rate of decline in FEV₁:new insight into gender differences. *Eur Respir J*;7(6):1056-61.
306. *Yamamoto C., Yoneda T., Yoshikawa M., Fu A., Tokuyama T. and Tsukaguchi K. (1997):* Airway inflammation in COPD assessed by sputum levels of interleukin-8. *Chest*; 112: 505-10.
307. *Yang W-S, Lee W-J, Funahashi T, Tanaka S, Matsuzawa Y, Chao C-L, Chen C-L, Tai T-Y, Lee-Ming Chuang LM, et al. (2001):* Weight Reduction Increases Plasma Levels of an Adipose-Derived Anti-Inflammatory Protein, Adiponectin. *J Clin Endocrinol Metab*; 86: 3815-9.
308. *Young RP, Hopkins RJ, Christmas T, Black PN, and Metcalf P, (2009):* COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. *Eur Respir J* 34: 380–386.
309. *Zeng, Q, Isobe, K, Fu, L, et al. (2007):* Effects of exercise on adiponectin and adiponectin receptor levels in rats. *Life Sci*;80,454-459